Body mass index and mortality in prostate cancer patients: A dose-response meta-analysis

Prostate Cancer and Prostatic Diseases

Volumn 19, Issue 2, 2016, Pages 122-131

  Zhong, S ^a   Yan, X ^b   Wu, Y ^a   Zhang, X ^a   Chen, L ^c   Tang, J ^a   Zhao, J ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BODY MASS; CANCER DIAGNOSIS; CANCER MORTALITY; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; CAUSE OF DEATH; MALE; META ANALYSIS; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; PUBLISHING;

BODY MASS INDEX; CASE-CONTROL STUDIES; CAUSE OF DEATH; COHORT STUDIES; HUMANS; MALE; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; PUBLICATION BIAS;

EID: 84954342015     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.64     Document Type: Review

References (62)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29
2. Haque R, Van Den Eeden SK, Wallner LP, Richert-Boe K, Kallakury B, Wang R, et al. Association of body mass index and prostate cancer mortality. Obes Res Clin Pract 2014; 8: e374-e381
3. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2011; 4: 486-501
4. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269
5. Wells G, Shea B, O'Connell D, Robertson J, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2010. www.ohri.ca/programs/clinical-epidemiology/oxford-web.ppt
6. Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat 2005; 30: 261-293
7. Raudenbush SW. Analyzing effect sizes: random-effects models. In: Cooper H, Hedges LV, Valentine JC (eds). The handbook of research synthesis and meta-analysis, Vol. 2. Russell Sage Foundation: New York, 2009, pp 295-316
8. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011; 342: d549
9. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109: 1192-1202
10. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001; 10: 345-353
11. Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, et al. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. J Urol 2007; 178: 1946-1951
12. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
13. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychol Methods 2001; 6: 203-217
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
15. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135: 1301-1309
16. Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997; 89: 385-389
17. Gapstur SM, Gann PH, Colangelo LA, Barron-Simpson R, Kopp P, Dyer A, et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control 2001; 12: 763-772
18. Huxley R, Ansary-Mohaddam A, Huxley R, Barzi F, Lam TH, Jamrozik K, et al. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev 2007; 8: 199-205
19. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-684
20. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039-1047
21. Dehal A, Garrett T, Tedders SH, Arroyo C, Afriyie-Gyawu E, Zhang J. Body mass index and death rate of colorectal cancer among a national cohort of U.S. adults. Nutr Cancer 2011; 63: 1218-1225
22. Discacciati A, Orsini N, Andersson SO, Andren O, Johansson JE, Wolk A. Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer 2011; 105: 1061-1068
23. Bassett JK, Severi G, Baglietto L, MacInnis RJ, Hoang HN, Hopper JL, et al. Weight change and prostate cancer incidence and mortality. Int J Cancer 2012; 131: 1711-1719
24. Moller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L, et al. Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark. Int J Cancer 2015; 136: 1940-1947
25. Taghizadeh N, Boezen HM, Schouten JP, Schroder CP, Elisabeth De Vries EG, Vonk JM. BMI and lifetime changes in BMI and cancer mortality risk. PLoS One 2015; 10: e0125261
26. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer 2007; 110: 2691-2699
27. Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Adamovich E. Obesity is not predictive of overall survival following permanent prostate brachytherapy. Am J Clin Oncol 2007; 30: 588-596
28. Bonn SE, Wiklund F, Sjolander A, Szulkin R, Stattin P, Holmberg E, et al. Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes Control 2014; 25: 933-943
29. Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Alai H, Feng Z, et al. Obesity and long-term survival after radical prostatectomy. J Urol 2014; 192: 1100-1104
30. Davies BJ, Smaldone MC, Sadetsky N, Dall'era M, Carroll PR. The impact of obesity on overall and cancer specific survival in men with prostate cancer. J Urol 2009; 182: 112-117
31. Armstrong AJ, Halabi S, De Wit R, Tannock IF, Eisenberger M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostat Dis 2009; 12: 88-93
32. Froehner M, Kellner AE, Koch R, Baretton GB, Hakenberg OW, Wirth MP. A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. BMC Urol 2014; 14: 28
33. Cantarutti A, Bonn SE, Adami HO, Gronberg H, Bellocco R, Balter K. Body mass index and mortality in men with prostate cancer. Prostate 2015; 75: 1129-1136
34. Eichholzer M, Bernasconi F, Jordan P, Stahelin HB. Body mass index and the risk of male cancer mortality of various sites: 17-year follow-up of the Basel cohort study. Swiss Med Wkly 2005; 135: 27-33
35. Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, et al. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer 2006; 107: 521-529
36. Schwartz GG, Skinner HG. A prospective study of total and ionized serum calcium and time to fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 1768-1773
37. Tendulkar RD, Hunter GK, Reddy CA, Stephans KL, Ciezki JP, Abdel-Wahab M, et al. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2013; 87: 94-99
38. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 1-48
39. Crippa A, Orsini N. Dosresmeta: Performing Multivariate Dose-response Meta-analysis. R Foundation for Statistical Computing: Vienna, Austria, 2013
40. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2: ERG. J Natl Cancer Inst 2013; 105: 1881-1890
41. Parr CL, Batty GD, Lam TH, Barzi F, Fang X, Ho SC, et al. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. Lancet Oncol 2010; 11: 741-752
42. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121: 1571-1578
43. Halabi S, Small EJ, Vogelzang NJ. Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23: 2434-2435
44. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638
45. Gozen AS, Akin Y, Ozden E, Ates M, Hruza M, Rassweiler J. Impact of body mass index on outcomes of laparoscopic radical prostatectomy with long-term follow-up. Scand J Urol 2015; 49: 70-76
46. Xu H, Zhang LM, Liu J, Ding GX, Ding Q, Jiang HW. The association between overall survival of prostate cancer patients and hypertension, hyperglycemia, and overweight in Southern China: a prospective cohort study. J Cancer Res Clin Oncol 2013; 139: 943-951
47. Palma D, Pickles T, Tyldesley S. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU Int 2007; 100: 315-319
48. Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.Cancer 2007; 110: 1478-1484
49. Pfitzenmaier J, Pritsch M, Haferkamp A, Jakobi H, Fritsch F, Gilfrich C, et al. Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?. BJU Int 2009; 103: 877-882
50. Burton A, Martin R, Galobardes B, Davey Smith G, Jeffreys M. Young adulthood body mass index and risk of cancer in later adulthood: historical cohort study. Cancer Causes Control 2010; 21: 2069-2077
51. Han M, Trock BJ, Partin AW, Humphreys EB, Bivalacqua TJ, Guzzo TJ, et al. The impact of preoperative erectile dysfunction on survival after radical prostatectomy. BJU Int 2010; 106: 1612-1617
52. Van Roermund JG, Hinnen KA, Battermann JJ, Witjes JA, Bosch JL, Kiemeney LA, et al. Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy. BJU Int 2010; 105: 42-48
53. Haggstrom C, Stocks T, Ulmert D, Bjorge T, Ulmer H, Hallmans G, et al. Prospective study on metabolic factors and risk of prostate cancer. Cancer 2012; 118: 6199-6206
54. Park JM, Nam JS, Na W, Oh JJ, Lee S, Hong SK, et al. Prognostic value of body mass index in korean patients with castration-resistant prostate cancer. Korean J Urol 2012; 53: 761-765
55. Fowke JH, McLerran DF, Gupta PC, He J, Shu XO, Ramadas K, et al. Associations of Body Mass Index, Smoking, and Alcohol Consumption With Prostate Cancer Mortality in the Asia Cohort Consortium. Am J Epidemiol 2015; 182: 381-389
56. Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, et al. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model. Eur Urol 2015; 68: 196-204
57. Mohammed AA, El-Tanni H, Ghanem HM, Farooq MU, El Saify AM, Al-Zahrani AS, et al. Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer. J Egypt Ntl Canc Inst 2015; 27: 155-159
58. Park SM, Lim MK, Shin SA, Yun YH. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 2006; 24: 5017-5024
59. Gann PH, Daviglus ML, Dyer AR, Stamler J. Heart rate and prostate cancer mortality: results of a prospective analysis. Cancer Epidemiol Biomarkers Prev 1995; 4: 611-616
60. Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res 2012; 2012: 789174
61. Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol 2012; 35: 504-509
62. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 2000; 163: 824-827